How Cosentyx Controls Psoriasis Over Time
Cosentyx (secukinumab), an IL-17A inhibitor, reduces psoriasis symptoms by targeting inflammation at its source. In clinical trials like FUTURE 5 (5 years of data), 80-90% of patients maintained clear or almost clear skin (PASI 90 response) after initial response, with sustained improvements in plaque severity, itching, and scaling.[1][2] Real-world studies, such as a 5-year German registry, show 70-85% of moderate-to-severe plaque psoriasis patients retain at least PASI 75 response, outperforming short-term methotrexate or cyclosporine.[3]
Do Symptoms Return If You Stop Long-Term Use?
Discontinuation often leads to relapse. In extension trials, stopping after 2-5 years caused psoriasis to rebound to baseline severity within 6-12 months in 60-80% of cases, due to the drug's disease-modifying but not curative effect.[1][4] Restarting restores response in most patients, but repeated cycles may slightly reduce efficacy over time.
What Happens After 5+ Years of Continuous Use?
Long-term data from SCRATCH (up to 7 years) and other registries indicate durable efficacy: 65% achieve PASI 90 at year 5, dropping minimally to 60% at year 7, with low progression to psoriatic arthritis.[2][5] Nail and scalp psoriasis also improve progressively, with 50-70% clearance by year 3.
Common Long-Term Side Effects Patients Experience
Upper respiratory infections occur in 20-30% over years, but serious risks like IBD flare-ups (rare, <1%) or candidiasis (5-10%) stabilize or decline after year 1.[1][6] No increased skin cancer signal in 5-year data; monitoring for latent TB remains standard.
How Does It Compare to Other Biologics Long-Term?
| Biologic | 5-Year PASI 90 Rate | Relapse Risk on Stop | Key Long-Term Edge |
|----------|---------------------|----------------------|-------------------|
| Cosentyx | 70-80% | High (60-80%) | Strong scalp/nail control |
| Humira (adalimumab) | 50-60% | High | More injection-site reactions |
| Stelara (ustekinumab) | 60-70% | Moderate | Slower onset |
| Tremfya (guselkumab) | 65-75% | High | Similar IL profile, fewer infections |
Cosentyx shows superior long-term skin clearance vs. TNF inhibitors but matches IL-23s.[3][7]
Who Responds Best and Who Might Not?
Best responders: moderate-severe plaque psoriasis without obesity (BMI >30 cuts efficacy by 20%). Poor responders: prior biologic failures or high baseline PASI (>20).[4] Pediatric data (up to 2 years) mirrors adults, with 75% sustained clearance.[8]
Sources
[1] Novartis Cosentyx Label (FDA)
[2] JAAD: 5-Year Efficacy (FUTURE 5)
[3] J Eur Acad Dermatol Venereol: German Registry
[4] Lancet: Withdrawal Study
[5] Br J Dermatol: SCRATCH
[6] Safety Review (Uppsala Monitoring)
[7] Head-to-Head Meta-Analysis (JAMA Derm)
[8] Pediatrics Trial (Novartis)